Articles tagged with: Selzentry
Headline, News »
Researchers presented several studies last week at the 2010 International AIDS Conference that focused on the relationship between HIV and aging.
Some of the studies found that HIV-related diseases and complications, such as osteoporosis, heart problems, and sexual dysfunction, are more prevalent in older adults with HIV.
However, several studies also showed positive results, including unexpected data showing HIV may not cause faster immune system and brain decline with age. Additional studies showed the benefits of exercise and strength training and the effectiveness of Selzentry (maraviroc) in older patients with…
Headline, News »
The United States Food and Drug Administration (FDA) approved changes last week in the prescription information for Selzentry (maraviroc) 150 mg and 300 mg tablets.
The new information states that Selzentry is contraindicated and should not be taken by individuals with severe kidney impairment or end-stage renal (kidney) disease (ESRD) who are taking strong CYP3A inhibitors or inducers, which includes the antiretroviral Norvir (ritonavir).
The FDA also recommends that patients with severe kidney impairment or ESRD not take Selzentry unless no alternative treatments are available.
CYP3A is a family of…
Headline, News »
On October 8, the Antiviral Drugs Advisory Committee of the Food and Drug Administration (FDA) recommended approval of Selzentry (maraviroc) for use in treatment-naïve patients. The Committee voted 10-4 in favor of extending Selzentry’s use to newly diagnosed individuals, but the FDA has yet to grant official approval.
Selzentry was originally approved for treatment-experienced patients in 2007. Pfizer, Selzentry’s manufacturer, applied for its expanded use in September after receiving results from study 1026.
Study 1026 compared a 300 mg dose of Selzentry given twice daily in combination with Combivir (zidovudine/lamivudine)…
Resources »
Fusion inhibitors are a new class of drugs offered to patients with HIV-1 strains resistant to standard drug treatment. The U.S. Food and Drug Administration (FDA) approved Trimeris and Hoffmann-La Roche’s Fuzeon (enfuvirtide) in March 2003 and Pfizer’s Selzentry (maraviroc) in August 2007 to accompany current antiviral regimens.
Fuzeon is injected into the body, while Selzentry is taken orally. Both drugs work by preventing the virus from entering and infecting human immune cells. Fuzeon binds to an HIV protein and blocks its necessary conformational change to bring the viral…